Avrobio Inc (AVRO)
1.495
+0.08
(+6.03%)
USD |
NASDAQ |
May 24, 13:34
Avrobio Cash from Financing (TTM): -16.05M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -16.05M |
December 31, 2023 | -16.03M |
September 30, 2023 | -16.03M |
June 30, 2023 | -16.15M |
March 31, 2023 | 0.175M |
December 31, 2022 | 0.262M |
September 30, 2022 | 15.15M |
June 30, 2022 | 15.11M |
March 31, 2022 | 29.71M |
December 31, 2021 | 30.37M |
September 30, 2021 | 86.13M |
June 30, 2021 | 86.17M |
March 31, 2021 | 79.76M |
Date | Value |
---|---|
December 31, 2020 | 172.62M |
September 30, 2020 | 101.94M |
June 30, 2020 | 231.36M |
March 31, 2020 | 223.40M |
December 31, 2019 | 129.99M |
September 30, 2019 | 129.82M |
June 30, 2019 | -2.904M |
March 31, 2019 | 102.33M |
December 31, 2018 | 160.29M |
September 30, 2018 | 174.39M |
June 30, 2018 | 177.62M |
March 31, 2018 | 72.09M |
December 31, 2017 | 17.37M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-16.15M
Minimum
Jun 2023
231.36M
Maximum
Jun 2020
63.24M
Average
30.04M
Median
Cash from Financing (TTM) Benchmarks
Axonics Inc | -5.062M |
Catalent Inc | 33.00M |
AIM ImmunoTech Inc | 3.214M |
Protalix BioTherapeutics Inc | 10.43M |
Armata Pharmaceuticals Inc | 59.32M |